Medrio Assisting Hope Biosciences to Combat COVID-19 with New Stem Cell Clinical Trial

Share Article

Medrio supplies Hope Biosciences Stem Cell Research Foundation with EDC platform for Phase II clinical trial using adipose-derived mesenchymal stem cells to combat COVID-19.

"The Medrio team is thankful for the opportunity to partner with Hope Biosciences Stem Cell Research Foundation and be a part of the solution to testing treatment for COVID-19,” -Fred Martin, Chief Product Officer of Medrio.

Medrio, Inc. the leading provider of eClinical technology to pharmaceutical, biotech, medical device, diagnostics, and animal health markets, has entered into a partnership with Hope Biosciences Stem Cell Research Foundation - a non-profit research organization dedicated to translational research in regenerative medicine. The foundation is sponsoring three clinical trial protocols, all using mesenchymal stem cells to combat COVID-19.

Hope Biosciences, a biopharmaceutical company developing adult stem cell based therapeutics for a variety of indications, was approved by the FDA on April 10, 2020 for the second of three new protocols for COVID-19. Hope Biosciences’ proprietary core technology extracts mesenchymal stem cells from a very small amount of fat tissue and once purified, grows them into therapeutic quantities. Quantities large enough and repeatable enough to defend the body against COVID-19. This protocol will study the use of HB-adMSCs to protect against the virus. This trial will be open to those at high risk for contracting the virus, such as, frontline healthcare workers and law enforcement. This Phase II, randomized, double-blinded, placebo-controlled study will determine whether receiving allogeneic stem cells has an effect on hospitalization and symptoms due to COVID-19. As part of our continued partnership with Hope Biosciences, and in an effort to aid in the fight against COVID-19, Medrio is donating the electronic data capture platform for the duration of this clinical trial.

“We’ve worked with Medrio on other studies in the past. They are always willing to go the extra mile to help, and their sophisticated EDC system has worked well for us. When time is of the essence, we’re thankful we have Medrio as a partner to allow us to accelerate our study build so that we can get treatments to patients in need faster,” said Donna Chang, President & CEO of Hope Biosciences.

Medrio’s products, services and employees excel at expediting clinical trial study setup with their flexible and easy-to-configure electronic data capture platform. “We are committed to doing all that we can to help safely expedite clinical trials in the race to beat COVID-19. The Medrio team is thankful for the opportunity to partner with Hope Biosciences Stem Cell Research Foundation and be a part of the solution to testing treatment for COVID-19,” explains Fred Martin, Chief Product Officer of Medrio.

Medrio's EDC, services, and people provide one of the fastest solutions on the market to achieve first patient enrolled (FPI). The EDC accelerates study build with an intuitive drag-and-drop interface that also allows for mid-study changes without downtime. The electronic data capture platform allows for flexible data collection, real-time data monitoring, superior data accuracy, and the quickest database lock.

“I speak for all of Medrio when I say that we are thankful for the work that Hope Biosciences is doing to find a treatment for COVID-19, and it’s our pleasure to provide our EDC services for this cause. We’re all in this together,” added Fred Martin.

About Medrio
Medrio is the leading provider of eClinical technology for pharma, device, and diagnostics clinical trials. Founded in 2005, the company’s cloud-based EDC, Direct Data Capture, eConsent, and ePRO solutions deliver fast, flexible, and easy-to-use tools for the collection and management of clinical data and patient-reported outcome responses. Study sponsors and Contract Research Organizations have used Medrio extensively in clinical trials across a wide array of therapeutic areas, with notable success in oncology, infectious disease, and more. Medrio has extensive experience in all study phases and leads the market in early-phase trials. The company serves over 600 customers globally, with headquarters in San Francisco and offices in numerous domestic and international locations. For more information, please visit http://www.medrio.com.

Interested in helping to fund this study? Please click https://ghcf.kimbia.com/hopebiosciences

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jillian Tygh
Medrio
800-958-0154
Email >
Visit website